Intra-Cellular Therapies EBITDA 2013-2022 | ITCI

Intra-Cellular Therapies annual and quarterly EBITDA history from 2013 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Intra-Cellular Therapies EBITDA for the quarter ending March 31, 2022 was $-0.077B, a 41.33% increase year-over-year.
  • Intra-Cellular Therapies EBITDA for the twelve months ending March 31, 2022 was $-0.312B, a 31.88% increase year-over-year.
  • Intra-Cellular Therapies 2021 annual EBITDA was $-0.289B, a 25.02% increase from 2020.
  • Intra-Cellular Therapies 2020 annual EBITDA was $-0.231B, a 49.58% increase from 2019.
  • Intra-Cellular Therapies 2019 annual EBITDA was $-0.155B, a 5.02% decline from 2018.
Intra-Cellular Therapies Annual EBITDA
(Millions of US $)
2021 $-289
2020 $-231
2019 $-155
2018 $-163
2017 $-102
2016 $-118
2015 $-105
2014 $-31
2013 $-26
2012 $-16
Intra-Cellular Therapies Quarterly EBITDA
(Millions of US $)
2022-03-31 $-77
2021-12-31 $-87
2021-09-30 $-79
2021-06-30 $-70
2021-03-31 $-54
2020-12-31 $-62
2020-09-30 $-56
2020-06-30 $-65
2020-03-31 $-49
2019-12-31 $-42
2019-09-30 $-36
2019-06-30 $-39
2019-03-31 $-37
2018-12-31 $-43
2018-09-30 $-44
2018-06-30 $-39
2018-03-31 $-37
2017-12-31 $-33
2017-09-30 $-24
2017-06-30 $-18
2017-03-31 $-28
2016-12-31 $-28
2016-09-30 $-30
2016-06-30 $-31
2016-03-31 $-28
2015-12-31 $-29
2015-09-30 $-32
2015-06-30 $-21
2015-03-31 $-22
2014-12-31 $-15
2014-09-30 $-6
2014-06-30 $-5
2014-03-31 $-5
2013-12-31 $-8
2013-09-30 $-5
2013-06-30 $-8
2013-03-31 $-5
2012-12-31
2012-09-30 $-2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.373B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00